nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—Gemcitabine—urinary bladder cancer	0.444	1	CrCtD
Zalcitabine—Lamivudine—Gemcitabine—urinary bladder cancer	0.132	0.558	CrCrCtD
Zalcitabine—SLC29A2—Gemcitabine—urinary bladder cancer	0.0732	0.317	CbGbCtD
Zalcitabine—Cytarabine—Gemcitabine—urinary bladder cancer	0.0546	0.232	CrCrCtD
Zalcitabine—Decitabine—Gemcitabine—urinary bladder cancer	0.0494	0.21	CrCrCtD
Zalcitabine—SLC29A1—Gemcitabine—urinary bladder cancer	0.042	0.182	CbGbCtD
Zalcitabine—DCK—Gemcitabine—urinary bladder cancer	0.039	0.169	CbGbCtD
Zalcitabine—SLC29A1—Fluorouracil—urinary bladder cancer	0.036	0.156	CbGbCtD
Zalcitabine—SLC22A7—Fluorouracil—urinary bladder cancer	0.0135	0.0586	CbGbCtD
Zalcitabine—SLC22A7—Methotrexate—urinary bladder cancer	0.00745	0.0323	CbGbCtD
Zalcitabine—CYP3A4—Thiotepa—urinary bladder cancer	0.00472	0.0205	CbGbCtD
Zalcitabine—CYP3A5—Etoposide—urinary bladder cancer	0.00328	0.0142	CbGbCtD
Zalcitabine—SLC22A6—Methotrexate—urinary bladder cancer	0.00317	0.0137	CbGbCtD
Zalcitabine—CYP2C9—Fluorouracil—urinary bladder cancer	0.00264	0.0114	CbGbCtD
Zalcitabine—CYP2C9—Cisplatin—urinary bladder cancer	0.00224	0.00971	CbGbCtD
Zalcitabine—CYP2D6—Doxorubicin—urinary bladder cancer	0.00137	0.00595	CbGbCtD
Zalcitabine—CYP3A4—Etoposide—urinary bladder cancer	0.00128	0.00555	CbGbCtD
Zalcitabine—Cytarabine—POLB—urinary bladder cancer	0.00106	0.538	CrCbGaD
Zalcitabine—SLC29A2—prostate gland—urinary bladder cancer	0.00101	0.108	CbGeAlD
Zalcitabine—CYP3A4—Doxorubicin—urinary bladder cancer	0.000873	0.00378	CbGbCtD
Zalcitabine—CYP2C9—urine—urinary bladder cancer	0.000678	0.0725	CbGeAlD
Zalcitabine—Gemcitabine—RRM2—urinary bladder cancer	0.000617	0.314	CrCbGaD
Zalcitabine—SLC29A2—female reproductive system—urinary bladder cancer	0.000551	0.0589	CbGeAlD
Zalcitabine—CYP3A4—urine—urinary bladder cancer	0.000517	0.0553	CbGeAlD
Zalcitabine—CYP2D6—urine—urinary bladder cancer	0.000509	0.0544	CbGeAlD
Zalcitabine—SLC29A1—prostate gland—urinary bladder cancer	0.0005	0.0535	CbGeAlD
Zalcitabine—SLC29A2—vagina—urinary bladder cancer	0.000498	0.0532	CbGeAlD
Zalcitabine—DCK—prostate gland—urinary bladder cancer	0.000478	0.0511	CbGeAlD
Zalcitabine—SLC22A7—renal system—urinary bladder cancer	0.000442	0.0472	CbGeAlD
Zalcitabine—DCK—Doxorubicin—Valrubicin—urinary bladder cancer	0.000405	0.375	CbGdCrCtD
Zalcitabine—DCK—Epirubicin—Valrubicin—urinary bladder cancer	0.000405	0.375	CbGdCrCtD
Zalcitabine—DCK—seminal vesicle—urinary bladder cancer	0.000404	0.0432	CbGeAlD
Zalcitabine—SLC29A1—renal system—urinary bladder cancer	0.000341	0.0364	CbGeAlD
Zalcitabine—SLC29A1—urethra—urinary bladder cancer	0.000335	0.0358	CbGeAlD
Zalcitabine—SLC29A2—lymph node—urinary bladder cancer	0.000322	0.0344	CbGeAlD
Zalcitabine—DCK—urethra—urinary bladder cancer	0.00032	0.0342	CbGeAlD
Zalcitabine—Gemcitabine—TYMS—urinary bladder cancer	0.00029	0.148	CrCbGaD
Zalcitabine—SLC29A1—female reproductive system—urinary bladder cancer	0.000273	0.0292	CbGeAlD
Zalcitabine—DCK—female reproductive system—urinary bladder cancer	0.000261	0.0279	CbGeAlD
Zalcitabine—CYP3A5—prostate gland—urinary bladder cancer	0.000247	0.0264	CbGeAlD
Zalcitabine—SLC29A1—vagina—urinary bladder cancer	0.000247	0.0264	CbGeAlD
Zalcitabine—DCK—vagina—urinary bladder cancer	0.000236	0.0252	CbGeAlD
Zalcitabine—CYP3A5—renal system—urinary bladder cancer	0.000169	0.018	CbGeAlD
Zalcitabine—SLC29A1—lymph node—urinary bladder cancer	0.00016	0.0171	CbGeAlD
Zalcitabine—DCK—lymph node—urinary bladder cancer	0.000153	0.0163	CbGeAlD
Zalcitabine—DCK—Doxorubicin—Epirubicin—urinary bladder cancer	0.000141	0.13	CbGdCrCtD
Zalcitabine—CYP2C9—female reproductive system—urinary bladder cancer	0.000133	0.0142	CbGeAlD
Zalcitabine—DCK—Epirubicin—Doxorubicin—urinary bladder cancer	0.00013	0.121	CbGdCrCtD
Zalcitabine—CYP3A4—renal system—urinary bladder cancer	0.000127	0.0135	CbGeAlD
Zalcitabine—CYP2D6—renal system—urinary bladder cancer	0.000125	0.0133	CbGeAlD
Zalcitabine—CYP3A5—vagina—urinary bladder cancer	0.000122	0.0131	CbGeAlD
Zalcitabine—CYP3A4—female reproductive system—urinary bladder cancer	0.000101	0.0108	CbGeAlD
Zalcitabine—CYP2D6—female reproductive system—urinary bladder cancer	9.97e-05	0.0107	CbGeAlD
Zalcitabine—CYP3A43—Metabolism—GSTO2—urinary bladder cancer	3.78e-05	0.00144	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—NAT1—urinary bladder cancer	3.78e-05	0.00144	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	3.77e-05	0.00143	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	3.74e-05	0.00142	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	3.72e-05	0.00141	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	3.69e-05	0.0014	CbGpPWpGaD
Zalcitabine—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	3.53e-05	0.00134	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	3.52e-05	0.00134	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—UGT2B7—urinary bladder cancer	3.51e-05	0.00134	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	3.48e-05	0.00132	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—UGT2B7—urinary bladder cancer	3.46e-05	0.00132	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	3.27e-05	0.00125	CbGpPWpGaD
Zalcitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	3.22e-05	0.00123	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—CYP4B1—urinary bladder cancer	3.16e-05	0.0012	CbGpPWpGaD
Zalcitabine—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	3.16e-05	0.0012	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	3.16e-05	0.0012	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CYP4B1—urinary bladder cancer	3.11e-05	0.00118	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	3.11e-05	0.00118	CbGpPWpGaD
Zalcitabine—Dizziness—Thiotepa—urinary bladder cancer	3.06e-05	0.000596	CcSEcCtD
Zalcitabine—Abdominal distension—Doxorubicin—urinary bladder cancer	3.05e-05	0.000595	CcSEcCtD
Zalcitabine—Urticaria—Fluorouracil—urinary bladder cancer	3.04e-05	0.000592	CcSEcCtD
Zalcitabine—Dysphagia—Doxorubicin—urinary bladder cancer	3.03e-05	0.000591	CcSEcCtD
Zalcitabine—Pollakiuria—Epirubicin—urinary bladder cancer	3.02e-05	0.00059	CcSEcCtD
Zalcitabine—Body temperature increased—Fluorouracil—urinary bladder cancer	3.02e-05	0.00059	CcSEcCtD
Zalcitabine—Eosinophilia—Doxorubicin—urinary bladder cancer	3e-05	0.000585	CcSEcCtD
Zalcitabine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	2.99e-05	0.00114	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	2.99e-05	0.00114	CbGpPWpGaD
Zalcitabine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	2.99e-05	0.000583	CcSEcCtD
Zalcitabine—DCK—Metabolism—SLC19A1—urinary bladder cancer	2.99e-05	0.00114	CbGpPWpGaD
Zalcitabine—Feeling abnormal—Cisplatin—urinary bladder cancer	2.99e-05	0.000583	CcSEcCtD
Zalcitabine—Pancreatitis—Doxorubicin—urinary bladder cancer	2.97e-05	0.000579	CcSEcCtD
Zalcitabine—Weight decreased—Epirubicin—urinary bladder cancer	2.96e-05	0.000578	CcSEcCtD
Zalcitabine—Dyspnoea—Etoposide—urinary bladder cancer	2.96e-05	0.000577	CcSEcCtD
Zalcitabine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	2.95e-05	0.00112	CbGpPWpGaD
Zalcitabine—Hyperglycaemia—Epirubicin—urinary bladder cancer	2.95e-05	0.000576	CcSEcCtD
Zalcitabine—Somnolence—Etoposide—urinary bladder cancer	2.95e-05	0.000576	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—SLC19A1—urinary bladder cancer	2.94e-05	0.00112	CbGpPWpGaD
Zalcitabine—Epistaxis—Methotrexate—urinary bladder cancer	2.94e-05	0.000574	CcSEcCtD
Zalcitabine—Vomiting—Thiotepa—urinary bladder cancer	2.94e-05	0.000573	CcSEcCtD
Zalcitabine—Rash—Thiotepa—urinary bladder cancer	2.91e-05	0.000569	CcSEcCtD
Zalcitabine—Dermatitis—Thiotepa—urinary bladder cancer	2.91e-05	0.000568	CcSEcCtD
Zalcitabine—DCK—Metabolism—PRSS3—urinary bladder cancer	2.91e-05	0.00111	CbGpPWpGaD
Zalcitabine—Headache—Thiotepa—urinary bladder cancer	2.9e-05	0.000565	CcSEcCtD
Zalcitabine—Decreased appetite—Etoposide—urinary bladder cancer	2.89e-05	0.000563	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—PRSS3—urinary bladder cancer	2.87e-05	0.00109	CbGpPWpGaD
Zalcitabine—Body temperature increased—Cisplatin—urinary bladder cancer	2.86e-05	0.000559	CcSEcCtD
Zalcitabine—Fatigue—Etoposide—urinary bladder cancer	2.86e-05	0.000558	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	2.86e-05	0.000558	CcSEcCtD
Zalcitabine—Jaundice—Epirubicin—urinary bladder cancer	2.84e-05	0.000555	CcSEcCtD
Zalcitabine—Pain—Etoposide—urinary bladder cancer	2.84e-05	0.000554	CcSEcCtD
Zalcitabine—Dysuria—Doxorubicin—urinary bladder cancer	2.83e-05	0.000552	CcSEcCtD
Zalcitabine—Neutropenia—Doxorubicin—urinary bladder cancer	2.83e-05	0.000552	CcSEcCtD
Zalcitabine—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	2.82e-05	0.00107	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	2.82e-05	0.00107	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Fluorouracil—urinary bladder cancer	2.82e-05	0.000549	CcSEcCtD
Zalcitabine—Hepatitis—Methotrexate—urinary bladder cancer	2.8e-05	0.000546	CcSEcCtD
Zalcitabine—Pollakiuria—Doxorubicin—urinary bladder cancer	2.8e-05	0.000546	CcSEcCtD
Zalcitabine—Asthenia—Gemcitabine—urinary bladder cancer	2.79e-05	0.000544	CcSEcCtD
Zalcitabine—Pharyngitis—Methotrexate—urinary bladder cancer	2.78e-05	0.000542	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	2.76e-05	0.000539	CcSEcCtD
Zalcitabine—Epistaxis—Epirubicin—urinary bladder cancer	2.75e-05	0.000537	CcSEcCtD
Zalcitabine—Pruritus—Gemcitabine—urinary bladder cancer	2.75e-05	0.000537	CcSEcCtD
Zalcitabine—Weight decreased—Doxorubicin—urinary bladder cancer	2.74e-05	0.000534	CcSEcCtD
Zalcitabine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	2.74e-05	0.00104	CbGpPWpGaD
Zalcitabine—Sinusitis—Epirubicin—urinary bladder cancer	2.74e-05	0.000534	CcSEcCtD
Zalcitabine—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	2.74e-05	0.00104	CbGpPWpGaD
Zalcitabine—Feeling abnormal—Etoposide—urinary bladder cancer	2.74e-05	0.000534	CcSEcCtD
Zalcitabine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	2.73e-05	0.000533	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Etoposide—urinary bladder cancer	2.71e-05	0.00053	CcSEcCtD
Zalcitabine—Pruritus—Fluorouracil—urinary bladder cancer	2.7e-05	0.000528	CcSEcCtD
Zalcitabine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	2.7e-05	0.00103	CbGpPWpGaD
Zalcitabine—Visual impairment—Methotrexate—urinary bladder cancer	2.7e-05	0.000526	CcSEcCtD
Zalcitabine—Hypersensitivity—Cisplatin—urinary bladder cancer	2.67e-05	0.000521	CcSEcCtD
Zalcitabine—Diarrhoea—Gemcitabine—urinary bladder cancer	2.66e-05	0.000519	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	2.65e-05	0.000516	CcSEcCtD
Zalcitabine—Urticaria—Etoposide—urinary bladder cancer	2.64e-05	0.000515	CcSEcCtD
Zalcitabine—Jaundice—Doxorubicin—urinary bladder cancer	2.63e-05	0.000513	CcSEcCtD
Zalcitabine—Rhinitis—Epirubicin—urinary bladder cancer	2.63e-05	0.000512	CcSEcCtD
Zalcitabine—Body temperature increased—Etoposide—urinary bladder cancer	2.62e-05	0.000512	CcSEcCtD
Zalcitabine—Abdominal pain—Etoposide—urinary bladder cancer	2.62e-05	0.000512	CcSEcCtD
Zalcitabine—CYP3A7—Biological oxidations—GSTP1—urinary bladder cancer	2.62e-05	0.000998	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.62e-05	0.000997	CbGpPWpGaD
Zalcitabine—Hepatitis—Epirubicin—urinary bladder cancer	2.62e-05	0.000511	CcSEcCtD
Zalcitabine—Eye disorder—Methotrexate—urinary bladder cancer	2.62e-05	0.00051	CcSEcCtD
Zalcitabine—Diarrhoea—Fluorouracil—urinary bladder cancer	2.62e-05	0.00051	CcSEcCtD
Zalcitabine—Tinnitus—Methotrexate—urinary bladder cancer	2.61e-05	0.000509	CcSEcCtD
Zalcitabine—Asthenia—Cisplatin—urinary bladder cancer	2.6e-05	0.000507	CcSEcCtD
Zalcitabine—Pharyngitis—Epirubicin—urinary bladder cancer	2.6e-05	0.000507	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.59e-05	0.000984	CbGpPWpGaD
Zalcitabine—Epistaxis—Doxorubicin—urinary bladder cancer	2.55e-05	0.000497	CcSEcCtD
Zalcitabine—Sinusitis—Doxorubicin—urinary bladder cancer	2.53e-05	0.000494	CcSEcCtD
Zalcitabine—Dizziness—Fluorouracil—urinary bladder cancer	2.53e-05	0.000493	CcSEcCtD
Zalcitabine—Visual impairment—Epirubicin—urinary bladder cancer	2.52e-05	0.000492	CcSEcCtD
Zalcitabine—Chills—Methotrexate—urinary bladder cancer	2.51e-05	0.00049	CcSEcCtD
Zalcitabine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	2.51e-05	0.000954	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	2.49e-05	0.000946	CbGpPWpGaD
Zalcitabine—Diarrhoea—Cisplatin—urinary bladder cancer	2.48e-05	0.000484	CcSEcCtD
Zalcitabine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	2.47e-05	0.000941	CbGpPWpGaD
Zalcitabine—Alopecia—Methotrexate—urinary bladder cancer	2.47e-05	0.000483	CcSEcCtD
Zalcitabine—Vomiting—Gemcitabine—urinary bladder cancer	2.47e-05	0.000482	CcSEcCtD
Zalcitabine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	2.47e-05	0.000938	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	2.45e-05	0.000933	CbGpPWpGaD
Zalcitabine—Rash—Gemcitabine—urinary bladder cancer	2.45e-05	0.000478	CcSEcCtD
Zalcitabine—Dermatitis—Gemcitabine—urinary bladder cancer	2.45e-05	0.000478	CcSEcCtD
Zalcitabine—Eye disorder—Epirubicin—urinary bladder cancer	2.45e-05	0.000478	CcSEcCtD
Zalcitabine—Hypersensitivity—Etoposide—urinary bladder cancer	2.45e-05	0.000477	CcSEcCtD
Zalcitabine—Tinnitus—Epirubicin—urinary bladder cancer	2.44e-05	0.000476	CcSEcCtD
Zalcitabine—Headache—Gemcitabine—urinary bladder cancer	2.44e-05	0.000475	CcSEcCtD
Zalcitabine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	2.43e-05	0.000925	CbGpPWpGaD
Zalcitabine—Flushing—Epirubicin—urinary bladder cancer	2.43e-05	0.000474	CcSEcCtD
Zalcitabine—Vomiting—Fluorouracil—urinary bladder cancer	2.43e-05	0.000474	CcSEcCtD
Zalcitabine—Rhinitis—Doxorubicin—urinary bladder cancer	2.43e-05	0.000474	CcSEcCtD
Zalcitabine—Hepatitis—Doxorubicin—urinary bladder cancer	2.42e-05	0.000473	CcSEcCtD
Zalcitabine—CYP3A7—Biological oxidations—GSTM1—urinary bladder cancer	2.41e-05	0.000917	CbGpPWpGaD
Zalcitabine—Rash—Fluorouracil—urinary bladder cancer	2.41e-05	0.00047	CcSEcCtD
Zalcitabine—Dermatitis—Fluorouracil—urinary bladder cancer	2.41e-05	0.00047	CcSEcCtD
Zalcitabine—Pharyngitis—Doxorubicin—urinary bladder cancer	2.41e-05	0.000469	CcSEcCtD
Zalcitabine—Headache—Fluorouracil—urinary bladder cancer	2.39e-05	0.000467	CcSEcCtD
Zalcitabine—Dysgeusia—Methotrexate—urinary bladder cancer	2.39e-05	0.000466	CcSEcCtD
Zalcitabine—Asthenia—Etoposide—urinary bladder cancer	2.38e-05	0.000465	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.38e-05	0.000904	CbGpPWpGaD
Zalcitabine—Back pain—Methotrexate—urinary bladder cancer	2.36e-05	0.00046	CcSEcCtD
Zalcitabine—Chills—Epirubicin—urinary bladder cancer	2.35e-05	0.000459	CcSEcCtD
Zalcitabine—Pruritus—Etoposide—urinary bladder cancer	2.35e-05	0.000458	CcSEcCtD
Zalcitabine—Arrhythmia—Epirubicin—urinary bladder cancer	2.34e-05	0.000457	CcSEcCtD
Zalcitabine—Visual impairment—Doxorubicin—urinary bladder cancer	2.34e-05	0.000456	CcSEcCtD
Zalcitabine—DCK—Metabolism—TYMP—urinary bladder cancer	2.33e-05	0.000885	CbGpPWpGaD
Zalcitabine—Alopecia—Epirubicin—urinary bladder cancer	2.31e-05	0.000452	CcSEcCtD
Zalcitabine—Vomiting—Cisplatin—urinary bladder cancer	2.3e-05	0.00045	CcSEcCtD
Zalcitabine—Vision blurred—Methotrexate—urinary bladder cancer	2.3e-05	0.000448	CcSEcCtD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.3e-05	0.000873	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—TYMP—urinary bladder cancer	2.29e-05	0.000872	CbGpPWpGaD
Zalcitabine—Rash—Cisplatin—urinary bladder cancer	2.28e-05	0.000446	CcSEcCtD
Zalcitabine—Dermatitis—Cisplatin—urinary bladder cancer	2.28e-05	0.000445	CcSEcCtD
Zalcitabine—Diarrhoea—Etoposide—urinary bladder cancer	2.27e-05	0.000443	CcSEcCtD
Zalcitabine—Eye disorder—Doxorubicin—urinary bladder cancer	2.26e-05	0.000442	CcSEcCtD
Zalcitabine—Ill-defined disorder—Methotrexate—urinary bladder cancer	2.26e-05	0.000441	CcSEcCtD
Zalcitabine—Tinnitus—Doxorubicin—urinary bladder cancer	2.26e-05	0.000441	CcSEcCtD
Zalcitabine—Anaemia—Methotrexate—urinary bladder cancer	2.25e-05	0.000439	CcSEcCtD
Zalcitabine—Flushing—Doxorubicin—urinary bladder cancer	2.25e-05	0.000439	CcSEcCtD
Zalcitabine—Flatulence—Epirubicin—urinary bladder cancer	2.25e-05	0.000438	CcSEcCtD
Zalcitabine—Tension—Epirubicin—urinary bladder cancer	2.24e-05	0.000437	CcSEcCtD
Zalcitabine—Dysgeusia—Epirubicin—urinary bladder cancer	2.23e-05	0.000436	CcSEcCtD
Zalcitabine—Nervousness—Epirubicin—urinary bladder cancer	2.21e-05	0.000432	CcSEcCtD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.21e-05	0.000841	CbGpPWpGaD
Zalcitabine—Back pain—Epirubicin—urinary bladder cancer	2.21e-05	0.00043	CcSEcCtD
Zalcitabine—Malaise—Methotrexate—urinary bladder cancer	2.2e-05	0.000429	CcSEcCtD
Zalcitabine—Dizziness—Etoposide—urinary bladder cancer	2.2e-05	0.000428	CcSEcCtD
Zalcitabine—Muscle spasms—Epirubicin—urinary bladder cancer	2.19e-05	0.000428	CcSEcCtD
Zalcitabine—Vertigo—Methotrexate—urinary bladder cancer	2.19e-05	0.000427	CcSEcCtD
Zalcitabine—Leukopenia—Methotrexate—urinary bladder cancer	2.18e-05	0.000426	CcSEcCtD
Zalcitabine—Chills—Doxorubicin—urinary bladder cancer	2.17e-05	0.000424	CcSEcCtD
Zalcitabine—Arrhythmia—Doxorubicin—urinary bladder cancer	2.16e-05	0.000422	CcSEcCtD
Zalcitabine—Vision blurred—Epirubicin—urinary bladder cancer	2.15e-05	0.000419	CcSEcCtD
Zalcitabine—Alopecia—Doxorubicin—urinary bladder cancer	2.14e-05	0.000418	CcSEcCtD
Zalcitabine—Cough—Methotrexate—urinary bladder cancer	2.13e-05	0.000415	CcSEcCtD
Zalcitabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	2.12e-05	0.000808	CbGpPWpGaD
Zalcitabine—Ill-defined disorder—Epirubicin—urinary bladder cancer	2.12e-05	0.000413	CcSEcCtD
Zalcitabine—Convulsion—Methotrexate—urinary bladder cancer	2.11e-05	0.000412	CcSEcCtD
Zalcitabine—Vomiting—Etoposide—urinary bladder cancer	2.11e-05	0.000412	CcSEcCtD
Zalcitabine—Anaemia—Epirubicin—urinary bladder cancer	2.11e-05	0.000411	CcSEcCtD
Zalcitabine—DCK—Metabolism—NAT2—urinary bladder cancer	2.1e-05	0.000801	CbGpPWpGaD
Zalcitabine—Agitation—Epirubicin—urinary bladder cancer	2.1e-05	0.000409	CcSEcCtD
Zalcitabine—Rash—Etoposide—urinary bladder cancer	2.09e-05	0.000408	CcSEcCtD
Zalcitabine—Dermatitis—Etoposide—urinary bladder cancer	2.09e-05	0.000408	CcSEcCtD
Zalcitabine—Headache—Etoposide—urinary bladder cancer	2.08e-05	0.000406	CcSEcCtD
Zalcitabine—Flatulence—Doxorubicin—urinary bladder cancer	2.08e-05	0.000406	CcSEcCtD
Zalcitabine—Myalgia—Methotrexate—urinary bladder cancer	2.07e-05	0.000405	CcSEcCtD
Zalcitabine—Arthralgia—Methotrexate—urinary bladder cancer	2.07e-05	0.000405	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—NAT2—urinary bladder cancer	2.07e-05	0.000788	CbGpPWpGaD
Zalcitabine—Tension—Doxorubicin—urinary bladder cancer	2.07e-05	0.000404	CcSEcCtD
Zalcitabine—Dysgeusia—Doxorubicin—urinary bladder cancer	2.07e-05	0.000403	CcSEcCtD
Zalcitabine—Malaise—Epirubicin—urinary bladder cancer	2.06e-05	0.000401	CcSEcCtD
Zalcitabine—Discomfort—Methotrexate—urinary bladder cancer	2.05e-05	0.0004	CcSEcCtD
Zalcitabine—Nervousness—Doxorubicin—urinary bladder cancer	2.05e-05	0.0004	CcSEcCtD
Zalcitabine—Vertigo—Epirubicin—urinary bladder cancer	2.05e-05	0.0004	CcSEcCtD
Zalcitabine—Syncope—Epirubicin—urinary bladder cancer	2.04e-05	0.000399	CcSEcCtD
Zalcitabine—Leukopenia—Epirubicin—urinary bladder cancer	2.04e-05	0.000398	CcSEcCtD
Zalcitabine—Back pain—Doxorubicin—urinary bladder cancer	2.04e-05	0.000398	CcSEcCtD
Zalcitabine—Muscle spasms—Doxorubicin—urinary bladder cancer	2.03e-05	0.000396	CcSEcCtD
Zalcitabine—Palpitations—Epirubicin—urinary bladder cancer	2.01e-05	0.000393	CcSEcCtD
Zalcitabine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	2.01e-05	0.000763	CbGpPWpGaD
Zalcitabine—Confusional state—Methotrexate—urinary bladder cancer	2e-05	0.000391	CcSEcCtD
Zalcitabine—Loss of consciousness—Epirubicin—urinary bladder cancer	2e-05	0.000391	CcSEcCtD
Zalcitabine—Cough—Epirubicin—urinary bladder cancer	1.99e-05	0.000388	CcSEcCtD
Zalcitabine—Vision blurred—Doxorubicin—urinary bladder cancer	1.99e-05	0.000388	CcSEcCtD
Zalcitabine—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	1.99e-05	0.000756	CbGpPWpGaD
Zalcitabine—Convulsion—Epirubicin—urinary bladder cancer	1.98e-05	0.000385	CcSEcCtD
Zalcitabine—Infection—Methotrexate—urinary bladder cancer	1.98e-05	0.000385	CcSEcCtD
Zalcitabine—Hypertension—Epirubicin—urinary bladder cancer	1.97e-05	0.000384	CcSEcCtD
Zalcitabine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	1.96e-05	0.000382	CcSEcCtD
Zalcitabine—Anaemia—Doxorubicin—urinary bladder cancer	1.95e-05	0.00038	CcSEcCtD
Zalcitabine—Thrombocytopenia—Methotrexate—urinary bladder cancer	1.95e-05	0.00038	CcSEcCtD
Zalcitabine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	1.95e-05	0.00074	CbGpPWpGaD
Zalcitabine—Arthralgia—Epirubicin—urinary bladder cancer	1.94e-05	0.000379	CcSEcCtD
Zalcitabine—Myalgia—Epirubicin—urinary bladder cancer	1.94e-05	0.000379	CcSEcCtD
Zalcitabine—Agitation—Doxorubicin—urinary bladder cancer	1.94e-05	0.000378	CcSEcCtD
Zalcitabine—Anxiety—Epirubicin—urinary bladder cancer	1.93e-05	0.000377	CcSEcCtD
Zalcitabine—Skin disorder—Methotrexate—urinary bladder cancer	1.93e-05	0.000377	CcSEcCtD
Zalcitabine—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	1.93e-05	0.000734	CbGpPWpGaD
Zalcitabine—Hyperhidrosis—Methotrexate—urinary bladder cancer	1.92e-05	0.000375	CcSEcCtD
Zalcitabine—Discomfort—Epirubicin—urinary bladder cancer	1.92e-05	0.000374	CcSEcCtD
Zalcitabine—Malaise—Doxorubicin—urinary bladder cancer	1.9e-05	0.000371	CcSEcCtD
Zalcitabine—Dry mouth—Epirubicin—urinary bladder cancer	1.9e-05	0.00037	CcSEcCtD
Zalcitabine—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	1.9e-05	0.000721	CbGpPWpGaD
Zalcitabine—Vertigo—Doxorubicin—urinary bladder cancer	1.9e-05	0.00037	CcSEcCtD
Zalcitabine—Anorexia—Methotrexate—urinary bladder cancer	1.9e-05	0.00037	CcSEcCtD
Zalcitabine—Syncope—Doxorubicin—urinary bladder cancer	1.89e-05	0.000369	CcSEcCtD
Zalcitabine—Leukopenia—Doxorubicin—urinary bladder cancer	1.89e-05	0.000368	CcSEcCtD
Zalcitabine—Confusional state—Epirubicin—urinary bladder cancer	1.88e-05	0.000366	CcSEcCtD
Zalcitabine—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.87e-05	0.000711	CbGpPWpGaD
Zalcitabine—Palpitations—Doxorubicin—urinary bladder cancer	1.86e-05	0.000364	CcSEcCtD
Zalcitabine—Oedema—Epirubicin—urinary bladder cancer	1.86e-05	0.000363	CcSEcCtD
Zalcitabine—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	1.86e-05	0.000708	CbGpPWpGaD
Zalcitabine—Loss of consciousness—Doxorubicin—urinary bladder cancer	1.85e-05	0.000362	CcSEcCtD
Zalcitabine—Infection—Epirubicin—urinary bladder cancer	1.85e-05	0.000361	CcSEcCtD
Zalcitabine—Cough—Doxorubicin—urinary bladder cancer	1.84e-05	0.000359	CcSEcCtD
Zalcitabine—Shock—Epirubicin—urinary bladder cancer	1.83e-05	0.000357	CcSEcCtD
Zalcitabine—Convulsion—Doxorubicin—urinary bladder cancer	1.83e-05	0.000357	CcSEcCtD
Zalcitabine—Thrombocytopenia—Epirubicin—urinary bladder cancer	1.82e-05	0.000355	CcSEcCtD
Zalcitabine—Hypertension—Doxorubicin—urinary bladder cancer	1.82e-05	0.000355	CcSEcCtD
Zalcitabine—DCK—Metabolism—RRM2—urinary bladder cancer	1.82e-05	0.000691	CbGpPWpGaD
Zalcitabine—Tachycardia—Epirubicin—urinary bladder cancer	1.82e-05	0.000354	CcSEcCtD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.82e-05	0.000691	CbGpPWpGaD
Zalcitabine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	1.81e-05	0.000353	CcSEcCtD
Zalcitabine—Skin disorder—Epirubicin—urinary bladder cancer	1.81e-05	0.000353	CcSEcCtD
Zalcitabine—Hyperhidrosis—Epirubicin—urinary bladder cancer	1.8e-05	0.000351	CcSEcCtD
Zalcitabine—Insomnia—Methotrexate—urinary bladder cancer	1.8e-05	0.000351	CcSEcCtD
Zalcitabine—Myalgia—Doxorubicin—urinary bladder cancer	1.8e-05	0.00035	CcSEcCtD
Zalcitabine—Arthralgia—Doxorubicin—urinary bladder cancer	1.8e-05	0.00035	CcSEcCtD
Zalcitabine—Anxiety—Doxorubicin—urinary bladder cancer	1.79e-05	0.000349	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—RRM2—urinary bladder cancer	1.79e-05	0.000681	CbGpPWpGaD
Zalcitabine—Discomfort—Doxorubicin—urinary bladder cancer	1.77e-05	0.000346	CcSEcCtD
Zalcitabine—Anorexia—Epirubicin—urinary bladder cancer	1.77e-05	0.000346	CcSEcCtD
Zalcitabine—Dyspnoea—Methotrexate—urinary bladder cancer	1.77e-05	0.000346	CcSEcCtD
Zalcitabine—Somnolence—Methotrexate—urinary bladder cancer	1.77e-05	0.000345	CcSEcCtD
Zalcitabine—Dry mouth—Doxorubicin—urinary bladder cancer	1.76e-05	0.000343	CcSEcCtD
Zalcitabine—Dyspepsia—Methotrexate—urinary bladder cancer	1.75e-05	0.000342	CcSEcCtD
Zalcitabine—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	1.74e-05	0.000663	CbGpPWpGaD
Zalcitabine—Confusional state—Doxorubicin—urinary bladder cancer	1.74e-05	0.000339	CcSEcCtD
Zalcitabine—Decreased appetite—Methotrexate—urinary bladder cancer	1.73e-05	0.000337	CcSEcCtD
Zalcitabine—Oedema—Doxorubicin—urinary bladder cancer	1.72e-05	0.000336	CcSEcCtD
Zalcitabine—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.72e-05	0.000654	CbGpPWpGaD
Zalcitabine—Fatigue—Methotrexate—urinary bladder cancer	1.71e-05	0.000334	CcSEcCtD
Zalcitabine—Infection—Doxorubicin—urinary bladder cancer	1.71e-05	0.000334	CcSEcCtD
Zalcitabine—Pain—Methotrexate—urinary bladder cancer	1.7e-05	0.000332	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	1.7e-05	0.000331	CcSEcCtD
Zalcitabine—Shock—Doxorubicin—urinary bladder cancer	1.69e-05	0.000331	CcSEcCtD
Zalcitabine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	1.69e-05	0.000329	CcSEcCtD
Zalcitabine—Insomnia—Epirubicin—urinary bladder cancer	1.68e-05	0.000328	CcSEcCtD
Zalcitabine—DCK—Metabolism—HPGDS—urinary bladder cancer	1.68e-05	0.00064	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—ENO2—urinary bladder cancer	1.68e-05	0.00064	CbGpPWpGaD
Zalcitabine—Tachycardia—Doxorubicin—urinary bladder cancer	1.68e-05	0.000328	CcSEcCtD
Zalcitabine—Skin disorder—Doxorubicin—urinary bladder cancer	1.67e-05	0.000326	CcSEcCtD
Zalcitabine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	1.66e-05	0.000325	CcSEcCtD
Zalcitabine—Dyspnoea—Epirubicin—urinary bladder cancer	1.66e-05	0.000324	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—HPGDS—urinary bladder cancer	1.66e-05	0.00063	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—ENO2—urinary bladder cancer	1.66e-05	0.00063	CbGpPWpGaD
Zalcitabine—Somnolence—Epirubicin—urinary bladder cancer	1.65e-05	0.000323	CcSEcCtD
Zalcitabine—Anorexia—Doxorubicin—urinary bladder cancer	1.64e-05	0.00032	CcSEcCtD
Zalcitabine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	1.64e-05	0.000624	CbGpPWpGaD
Zalcitabine—Feeling abnormal—Methotrexate—urinary bladder cancer	1.64e-05	0.00032	CcSEcCtD
Zalcitabine—Dyspepsia—Epirubicin—urinary bladder cancer	1.64e-05	0.00032	CcSEcCtD
Zalcitabine—DCK—Metabolism—GSTT1—urinary bladder cancer	1.63e-05	0.000621	CbGpPWpGaD
Zalcitabine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	1.63e-05	0.000317	CcSEcCtD
Zalcitabine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	1.62e-05	0.000615	CbGpPWpGaD
Zalcitabine—Decreased appetite—Epirubicin—urinary bladder cancer	1.62e-05	0.000316	CcSEcCtD
Zalcitabine—CYP3A7—Metabolism—GSTZ1—urinary bladder cancer	1.61e-05	0.000611	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—GSTT1—urinary bladder cancer	1.61e-05	0.000611	CbGpPWpGaD
Zalcitabine—Fatigue—Epirubicin—urinary bladder cancer	1.6e-05	0.000313	CcSEcCtD
Zalcitabine—Pain—Epirubicin—urinary bladder cancer	1.59e-05	0.00031	CcSEcCtD
Zalcitabine—Urticaria—Methotrexate—urinary bladder cancer	1.58e-05	0.000308	CcSEcCtD
Zalcitabine—Body temperature increased—Methotrexate—urinary bladder cancer	1.57e-05	0.000307	CcSEcCtD
Zalcitabine—Abdominal pain—Methotrexate—urinary bladder cancer	1.57e-05	0.000307	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	1.57e-05	0.000306	CcSEcCtD
Zalcitabine—Insomnia—Doxorubicin—urinary bladder cancer	1.56e-05	0.000304	CcSEcCtD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.55e-05	0.00059	CbGpPWpGaD
Zalcitabine—Dyspnoea—Doxorubicin—urinary bladder cancer	1.53e-05	0.0003	CcSEcCtD
Zalcitabine—Feeling abnormal—Epirubicin—urinary bladder cancer	1.53e-05	0.000299	CcSEcCtD
Zalcitabine—Somnolence—Doxorubicin—urinary bladder cancer	1.53e-05	0.000299	CcSEcCtD
Zalcitabine—CYP3A7—Metabolism—GSTO2—urinary bladder cancer	1.52e-05	0.00058	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—NAT1—urinary bladder cancer	1.52e-05	0.00058	CbGpPWpGaD
Zalcitabine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	1.52e-05	0.000297	CcSEcCtD
Zalcitabine—Dyspepsia—Doxorubicin—urinary bladder cancer	1.52e-05	0.000296	CcSEcCtD
Zalcitabine—Decreased appetite—Doxorubicin—urinary bladder cancer	1.5e-05	0.000292	CcSEcCtD
Zalcitabine—Fatigue—Doxorubicin—urinary bladder cancer	1.48e-05	0.00029	CcSEcCtD
Zalcitabine—Urticaria—Epirubicin—urinary bladder cancer	1.48e-05	0.000288	CcSEcCtD
Zalcitabine—Pain—Doxorubicin—urinary bladder cancer	1.47e-05	0.000287	CcSEcCtD
Zalcitabine—Abdominal pain—Epirubicin—urinary bladder cancer	1.47e-05	0.000287	CcSEcCtD
Zalcitabine—Body temperature increased—Epirubicin—urinary bladder cancer	1.47e-05	0.000287	CcSEcCtD
Zalcitabine—Hypersensitivity—Methotrexate—urinary bladder cancer	1.46e-05	0.000286	CcSEcCtD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	1.44e-05	0.000546	CbGpPWpGaD
Zalcitabine—Asthenia—Methotrexate—urinary bladder cancer	1.43e-05	0.000278	CcSEcCtD
Zalcitabine—Feeling abnormal—Doxorubicin—urinary bladder cancer	1.42e-05	0.000277	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.41e-05	0.000275	CcSEcCtD
Zalcitabine—Pruritus—Methotrexate—urinary bladder cancer	1.41e-05	0.000274	CcSEcCtD
Zalcitabine—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	1.39e-05	0.00053	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Epirubicin—urinary bladder cancer	1.37e-05	0.000267	CcSEcCtD
Zalcitabine—Urticaria—Doxorubicin—urinary bladder cancer	1.37e-05	0.000267	CcSEcCtD
Zalcitabine—Abdominal pain—Doxorubicin—urinary bladder cancer	1.36e-05	0.000266	CcSEcCtD
Zalcitabine—Body temperature increased—Doxorubicin—urinary bladder cancer	1.36e-05	0.000266	CcSEcCtD
Zalcitabine—Diarrhoea—Methotrexate—urinary bladder cancer	1.36e-05	0.000265	CcSEcCtD
Zalcitabine—DCK—Metabolism—NQO1—urinary bladder cancer	1.36e-05	0.000516	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	1.35e-05	0.000513	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	1.34e-05	0.000509	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—NQO1—urinary bladder cancer	1.34e-05	0.000508	CbGpPWpGaD
Zalcitabine—Asthenia—Epirubicin—urinary bladder cancer	1.34e-05	0.00026	CcSEcCtD
Zalcitabine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.33e-05	0.000506	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.32e-05	0.000502	CbGpPWpGaD
Zalcitabine—Pruritus—Epirubicin—urinary bladder cancer	1.32e-05	0.000257	CcSEcCtD
Zalcitabine—Dizziness—Methotrexate—urinary bladder cancer	1.31e-05	0.000257	CcSEcCtD
Zalcitabine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	1.31e-05	0.000499	CbGpPWpGaD
Zalcitabine—Diarrhoea—Epirubicin—urinary bladder cancer	1.27e-05	0.000248	CcSEcCtD
Zalcitabine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	1.27e-05	0.000484	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.27e-05	0.000248	CcSEcCtD
Zalcitabine—Vomiting—Methotrexate—urinary bladder cancer	1.26e-05	0.000247	CcSEcCtD
Zalcitabine—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	1.25e-05	0.000477	CbGpPWpGaD
Zalcitabine—Rash—Methotrexate—urinary bladder cancer	1.25e-05	0.000245	CcSEcCtD
Zalcitabine—Dermatitis—Methotrexate—urinary bladder cancer	1.25e-05	0.000244	CcSEcCtD
Zalcitabine—Headache—Methotrexate—urinary bladder cancer	1.25e-05	0.000243	CcSEcCtD
Zalcitabine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	1.24e-05	0.000471	CbGpPWpGaD
Zalcitabine—Asthenia—Doxorubicin—urinary bladder cancer	1.24e-05	0.000241	CcSEcCtD
Zalcitabine—Dizziness—Epirubicin—urinary bladder cancer	1.23e-05	0.00024	CcSEcCtD
Zalcitabine—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	1.23e-05	0.000467	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.22e-05	0.000465	CbGpPWpGaD
Zalcitabine—Pruritus—Doxorubicin—urinary bladder cancer	1.22e-05	0.000238	CcSEcCtD
Zalcitabine—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.21e-05	0.000461	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	1.18e-05	0.000451	CbGpPWpGaD
Zalcitabine—Vomiting—Epirubicin—urinary bladder cancer	1.18e-05	0.000231	CcSEcCtD
Zalcitabine—Diarrhoea—Doxorubicin—urinary bladder cancer	1.18e-05	0.00023	CcSEcCtD
Zalcitabine—Rash—Epirubicin—urinary bladder cancer	1.17e-05	0.000229	CcSEcCtD
Zalcitabine—Dermatitis—Epirubicin—urinary bladder cancer	1.17e-05	0.000229	CcSEcCtD
Zalcitabine—Headache—Epirubicin—urinary bladder cancer	1.17e-05	0.000227	CcSEcCtD
Zalcitabine—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	1.16e-05	0.000442	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	1.15e-05	0.000439	CbGpPWpGaD
Zalcitabine—Dizziness—Doxorubicin—urinary bladder cancer	1.14e-05	0.000222	CcSEcCtD
Zalcitabine—DCK—Metabolism—GSTP1—urinary bladder cancer	1.13e-05	0.00043	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—GSTP1—urinary bladder cancer	1.11e-05	0.000424	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	1.1e-05	0.000419	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—NAT1—urinary bladder cancer	1.1e-05	0.000419	CbGpPWpGaD
Zalcitabine—Vomiting—Doxorubicin—urinary bladder cancer	1.09e-05	0.000214	CcSEcCtD
Zalcitabine—Rash—Doxorubicin—urinary bladder cancer	1.09e-05	0.000212	CcSEcCtD
Zalcitabine—Dermatitis—Doxorubicin—urinary bladder cancer	1.08e-05	0.000212	CcSEcCtD
Zalcitabine—Headache—Doxorubicin—urinary bladder cancer	1.08e-05	0.00021	CcSEcCtD
Zalcitabine—DCK—Metabolism—TYMS—urinary bladder cancer	1.05e-05	0.0004	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—NCOR1—urinary bladder cancer	1.04e-05	0.000395	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—GSTM1—urinary bladder cancer	1.04e-05	0.000395	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—TYMS—urinary bladder cancer	1.04e-05	0.000394	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.03e-05	0.000394	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—GSTM1—urinary bladder cancer	1.02e-05	0.000389	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—NCOR1—urinary bladder cancer	1.02e-05	0.000389	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	1.01e-05	0.000383	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—GPX1—urinary bladder cancer	9.95e-06	0.000379	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—GPX1—urinary bladder cancer	9.8e-06	0.000373	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—ERCC2—urinary bladder cancer	9.77e-06	0.000372	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—ERCC2—urinary bladder cancer	9.62e-06	0.000366	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—TYMP—urinary bladder cancer	9.23e-06	0.000351	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—MTHFR—urinary bladder cancer	9.18e-06	0.000349	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	9.07e-06	0.000345	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—MTHFR—urinary bladder cancer	9.05e-06	0.000344	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	8.82e-06	0.000335	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.69e-06	0.000331	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	8.56e-06	0.000326	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—NAT2—urinary bladder cancer	8.35e-06	0.000318	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	8.35e-06	0.000317	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	8.26e-06	0.000314	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	8.19e-06	0.000312	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	8.1e-06	0.000308	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.99e-06	0.000304	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	7.83e-06	0.000298	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	7.83e-06	0.000298	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	7.76e-06	0.000295	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	7.76e-06	0.000295	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.63e-06	0.00029	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PPARG—urinary bladder cancer	7.45e-06	0.000283	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PPARG—urinary bladder cancer	7.33e-06	0.000279	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.26e-06	0.000276	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—RRM2—urinary bladder cancer	7.2e-06	0.000274	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	7.16e-06	0.000272	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—CREBBP—urinary bladder cancer	7.15e-06	0.000272	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	7.1e-06	0.00027	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CREBBP—urinary bladder cancer	7.05e-06	0.000268	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	6.67e-06	0.000254	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—ENO2—urinary bladder cancer	6.67e-06	0.000254	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—TYMP—urinary bladder cancer	6.67e-06	0.000254	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	6.47e-06	0.000246	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	6.45e-06	0.000245	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	6.39e-06	0.000243	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	6.09e-06	0.000232	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	6.04e-06	0.00023	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—NAT2—urinary bladder cancer	6.03e-06	0.00023	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	5.93e-06	0.000226	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	5.88e-06	0.000224	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PTGS2—urinary bladder cancer	5.86e-06	0.000223	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PTGS2—urinary bladder cancer	5.77e-06	0.00022	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.4e-06	0.000205	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—NQO1—urinary bladder cancer	5.38e-06	0.000205	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—RRM2—urinary bladder cancer	5.21e-06	0.000198	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.12e-06	0.000195	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.12e-06	0.000195	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PTEN—urinary bladder cancer	5.11e-06	0.000194	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PTEN—urinary bladder cancer	5.03e-06	0.000191	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—EP300—urinary bladder cancer	4.87e-06	0.000185	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—ENO2—urinary bladder cancer	4.82e-06	0.000184	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	4.82e-06	0.000184	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—EP300—urinary bladder cancer	4.8e-06	0.000183	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	4.74e-06	0.00018	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.72e-06	0.000179	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	4.7e-06	0.000179	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.68e-06	0.000178	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	4.68e-06	0.000178	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.52e-06	0.000172	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	4.49e-06	0.000171	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.29e-06	0.000163	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	4.25e-06	0.000162	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.22e-06	0.00016	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—TYMS—urinary bladder cancer	4.17e-06	0.000159	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	4.12e-06	0.000157	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	4.12e-06	0.000157	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.98e-06	0.000151	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—GPX1—urinary bladder cancer	3.95e-06	0.00015	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.89e-06	0.000148	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.88e-06	0.000148	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	3.88e-06	0.000147	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.7e-06	0.000141	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.67e-06	0.00014	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	3.64e-06	0.000139	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.43e-06	0.00013	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.43e-06	0.00013	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.4e-06	0.000129	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.4e-06	0.000129	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.38e-06	0.000129	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.33e-06	0.000127	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.3e-06	0.000125	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.25e-06	0.000124	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	3.24e-06	0.000123	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.1e-06	0.000118	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—TYMS—urinary bladder cancer	3.01e-06	0.000115	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.98e-06	0.000113	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.98e-06	0.000113	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PPARG—urinary bladder cancer	2.95e-06	0.000112	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.85e-06	0.000109	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	2.84e-06	0.000108	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.8e-06	0.000107	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.8e-06	0.000107	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.76e-06	0.000105	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.74e-06	0.000104	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.66e-06	0.000101	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.63e-06	0.0001	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.42e-06	9.21e-05	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	2.32e-06	8.84e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.32e-06	8.82e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.31e-06	8.77e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.29e-06	8.7e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.24e-06	8.53e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.24e-06	8.53e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.21e-06	8.41e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.17e-06	8.27e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.14e-06	8.16e-05	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PPARG—urinary bladder cancer	2.14e-06	8.12e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.13e-06	8.08e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.12e-06	8.06e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.12e-06	8.06e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.1e-06	7.99e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.1e-06	7.99e-05	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	2.05e-06	7.8e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.03e-06	7.72e-05	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PTEN—urinary bladder cancer	2.03e-06	7.71e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.01e-06	7.65e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.99e-06	7.58e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.97e-06	7.51e-05	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.93e-06	7.35e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.87e-06	7.12e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.86e-06	7.06e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.81e-06	6.88e-05	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.68e-06	6.39e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.52e-06	5.78e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.51e-06	5.74e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.51e-06	5.73e-05	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.47e-06	5.57e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.46e-06	5.55e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.45e-06	5.5e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.4e-06	5.33e-05	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.4e-06	5.32e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.39e-06	5.27e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.39e-06	5.27e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.33e-06	5.05e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.3e-06	4.96e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.22e-06	4.66e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.19e-06	4.54e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.18e-06	4.51e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.04e-06	3.96e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.03e-06	3.93e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—EP300—urinary bladder cancer	9.93e-07	3.78e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.93e-07	3.78e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—EP300—urinary bladder cancer	9.85e-07	3.75e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.54e-07	3.63e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.81e-07	2.97e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.81e-07	2.59e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.5e-07	2.47e-05	CbGpPWpGaD
